Zhitong Finance App News, Eddy Pharmaceutical (688488.SH) issued an announcement. Recently, the company and its wholly-owned subsidiaries Chengdu Eddy Pharmaceutical Technology Co., Ltd. and Nanjing Eddy Pharmaceutical Technology Co., Ltd. received the “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration, agreeing that the company is developing a Class 1 new drug ADC118 to carry out phase III clinical trials in the field of anti-AIDS.

Zhitongcaijing · 2d ago
Zhitong Finance App News, Eddy Pharmaceutical (688488.SH) issued an announcement. Recently, the company and its wholly-owned subsidiaries Chengdu Eddy Pharmaceutical Technology Co., Ltd. and Nanjing Eddy Pharmaceutical Technology Co., Ltd. received the “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration, agreeing that the company is developing a Class 1 new drug ADC118 to carry out phase III clinical trials in the field of anti-AIDS.